CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
NDA 21-073/S004

Trade Name: Actos

Generic Name: pioglitazone HCl

Sponsor: Takeda Pharmaceuticals Inc.

Approval Date: October 24, 2000

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 21-073/S004

CONTENTS

Reviews / Information Included in this NDA Review.	
Approval Letter	X
Approvable Letter	
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 21-073/S004

APPROVAL LETTER

NDA 21-073/S-004

Takeda Pharmaceuticals, Inc.
Attention: Robert Pilson, R.Ph.
Manager, Regulatory Compliance
475 Half Day Road, Suite 500
Lincolnshire, IL 60069

Dear Mr. Pilson:

Please refer to your supplemental new drug application dated June 13, 2000, received June 14, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Actos® (pioglitazone hydrochloride) 15 mg, 30 mg, and 45 mg Tablets.

This "Changes Being Effected in 30 Days" supplemental new drug application provides for the addition of the [redacted] site in [redacted] to act as an additional analytical testing facility for Actos.

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call Ms. Jena Weber, Regulatory Project Manager, at (301) 827-6422.

Sincerely,

Stephen K. Moore, Ph.D.
Chemistry Team Leader I, for
Division of Metabolic and Endocrine Drug Products (HFD-510)

DNDC II, Office of New Drug Chemistry
Center for Drug Evaluation and Research

cc:
Archival NDA 21-073
HFD-510/Div. Files
HFD-510/J.Weber
HFD-510/XYsern/SMoore
HFD-095/DDMS-IMT
HFD-820/DNDC Division Director
DISTRICT OFFICE

Drafted by: jmw/October 6, 2000
Initialed by:XYsern 10/6/SMoore 10/9/EGalliers 10/24/00
final:JWeber 10/25/00
filename: N21073.004

APPROVAL (AP)

/s/

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 21-073/S004

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW

Organization CDER/HFD-510 Division of Metabolism and Endocrine Drug Products	**NDA # 21-073** Approved: 21-JUL-1999
Name and Address of Applicant: Takeda Pharmaceuticals America Inc. 101 Carnegie Center, Suite 207 Princeton, NJ 08540 Phone: (609) 452-1113 x-4409 Fax: (609) 452-1218	**Supplement** SCS-004 Doc. 13-JUN-2000 Rec. 14-JUN-2000 **Name Of The Drug** Actos™ Tablets **Nonproprietary Name** Pioglitazone Hydrochloride Tablets
Supplement provides for the addition of [redacted] site at [redacted] additional analytical testing facility for Actos™ Tablets.	**New Correspondence** --

Pharmacological Category: Hypoglycemic Agent, treatment of NIDDM.	**How Dispensed** Oral Rx	**Supporting Documents** --
Dosage Form Tablets	**Potencies** 15-, 30- and 45-mg	

Chemical Name and Structure

Pioglitazone

$C_{19}H_{20}N_2O_3S \cdot HCl$
MW = 356.43 + 36.57 = 392.90



(±)-5[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione monohydrochloride

Comments: This Supplement –Changes Being Effected in 30 days- provides the addition of [redacted], facility at [redacted] as an additional analytical testing facility for Actos™ Tablets. In support of this submission the applicant, Takeda Pharmaceuticals, certifies that the tests methods approved in NDA 21-073 have been transferred to [redacted] utilizing an Approved Transfer Protocol. Relating to test methods, the applicant, has made no postapproval commitments. [redacted] has the capability to perform the intended testing and their [redacted] facility is in compliance with current Good Manufacturing Practices. The [redacted] has been found acceptable (based on the OC recommendation dated 02-OCT-2000) as an analytical testing facility by the District Office. A copy of the EER summary report, dated 02-OCT-2000, is attached. *Adequate information has been provided, and all regulatory requirements have been fulfilled.*

Conclusions and Recommendations The [redacted] has been found acceptable for analytical testing of the drug product, Actos™ (Pioglitazone HCl) Tablets. From the chemistry point of view, this supplement can be approved. Issue approval letter.

Reviewer Name (and signature) **Date Completed:** 02-OCT-2000

Xavier Ysern, PhD

R/D Init.

filename:

/nda/21073s04.doc

DISTRIBUTION: Original: NDA 21-073 cc: HFD-510 Division File/ JWeber / SMoore/ XYsern

CBE-30 days

AP

FDA CDER EES
ESTABLISHMENT EVALUATION REQUEST
SUMMARY REPORT

Application: **NDA 21073/004**
Stamp: **14-JUN-2000** Regulatory Due: **14-DEC-2000**
Applicant: **TAKEDA PHARMS**
475 HALF DAY RD STE 500
LINCOLNSHIRE, IL 60069

Priority: **1P** Org Code: **510**
Action Goal: District Goal: **09-NOV-2000**
Brand Name: **ACTOS (PIOGLITAZONE HCL)15/30/45MG TABS**
Established Name:
Generic Name: **PIOGLITAZONE HCL**
Dosage Form: **TAB (TABLET)**
Strength: **15-, 30- AND 45-MG**

FDA Contacts:			
	J. WEBER	**(HFD-510)**	**301-827-6422 , Project Manager**
	X. YSERN	**(HFD-510)**	**301-827-6420 , Review Chemist**
	S. MOORE	**(HFD-510)**	**301-827-6430 , Team Leader**

Overall Recommendation:

ACCEPTABLE on 02-OCT-2000 by J. D AMBROGIO (HFD-324) 301-827-0062

Establishment: [redacted]

DMF No:
AADA No:

Profile: **CTL** OAI Status: **NONE**
Last Milestone: **OC RECOMMENDATION**
Milestone Date: **02-OCT-2000**
Decision: **ACCEPTABLE**
Reason: **DISTRICT RECOMMENDATION**

Responsibilities: [redacted]